Pediatric cardiology Spontaneous closure of a large atrial septal defect in an infant

Fiszer, Roland; Szkutnik, Małgorzata; Chodór, Beata; Białkowski, Jacek

doi:10.5114/pwki.2014.46768

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The residual shunt rate after 6 months was 7% and it was not significantly higher compared to the Amplatzer PFO occluder (4%) [ 13 ]. Another low-volume registry showed promising results of CERA device implantation, with successful deployment in all cases and no complications observed during hospital stay and observation of up to 4 months [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke

Węglarz,

Węgiel,

Konarska-Kuszewska

et al. 2023

pwki

View full text Add to dashboard Cite

Introduction Nowadays, percutaneous closure of patent foramen ovale (PFO) in patients after cryptogenic stroke is becoming a dominating strategy. The most commonly used and investigated device is the Amplatzer occluder. However, several other devices have been designed for transcatheter closure of PFO, which are not so well examined. Aim To assess the effectiveness and safety of PFO closure with the Lifetech CERA occluder. Material and methods A prospective, single-arm registry of patients with PFO treated with CERA occluder (Lifetech Scientific, Shenzhen, China) implantation was conducted. We assessed peri-procedural and 12-month follow-up. Patients were screened for the residual shunt in transcranial Doppler/transesophageal echocardiography. Results Ninety-six patients entered the registry. Most patients were women (76%) and the analyzed group was relatively young (mean age of 42.3 ±13.6 years). Before closure, most patients had a large shunt through the PFO. Procedures of PFO closure were performed under TEE guidance. All procedures were made under local anesthesia and all patients had the PFO successfully closed. No device-related complications were reported in the peri-procedural period or during follow-up. No recurrent neurological ischemic events were reported at 12 months. During follow-up we observed a 9% rate of residual shunts, which were mostly small. Conclusions The study confirmed excellent immediate and 12-month results of CERA occluder implantation in patients with PFO.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The CERA PFO occluder (Lifetech Scientific, Shenzhen, China) is a transcatheter occlusion device for non-surgical PFO closure. Only small registries about CERA occluder implantation exist in patients with PFO [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke

Węglarz,

Węgiel,

Konarska-Kuszewska

et al. 2023

pwki

View full text Add to dashboard Cite

show abstract

“…It is also believed that significant ASDs should be closed around the age of four to five years. Our experience indicates that percutaneous closure of ASD is also feasible in infants and children below three years of age [7,8], but we have to remember that spontaneous closure of even large ASDs can occur [10].…”

Section: Resultsmentioning

confidence: 99%